| Product Name |
Composition |
Therapy |
| Spasgan tab |
metamizole sodium monohydrate 500.0 mg, pitofenone hydrochloride 5.0 mg, fenpiverinium bromide 0.1 mg, lactose monohydrate, povidone K-30, magnesium stearate, colloidal silicon dioxide |
non-narcotic analgesic and antispasmodic agent |
| Spasgan NEO |
Ibuprofen 400.0 mg, pitofenone hydrochloride 5.0 mg, fenpiverinium bromide 0,1 mg excipients (Maize Starch 88.0 mg, Microcrystalline Cellulose 85.9 mg, Sodium starch glycolate (type A) 14.7 mg, Alginic Acid 10.6 mg, Disodium Edetate Dihydrate 0.6 mg, Povidone (PVP K-90) 11.0 mg, Colloidal Silica (Aerosil 200) 7.0 mg, Croscarmellose sodium 4.7 mg, Sodium Lauryl Sulfate 2.4 mg, Magnesium Stearate 5.0 mg, Talc 5.0 mg, coating [Opadry II 85G68918 white (polyvinyl alcohol, 7.4 mg, titanium dioxide 5.76 mg, talc, 3.36 mg, macrogol 2.1 mg, soybean lecithin 0.58 mg) 19.2 mg] |
combined analgesic antispasmodic. |
| Spasgan inj |
metamizole sodium 500 mg, pitofenone hydrochloride 2 mg, fenpiverinium bromide 0.02 mg, water for injection up to 1 ml |
Analgesic non-narcotic and antispasmodic agent. |
| Wozulim-N |
recombinant human insulin 100 IU (3.5 mg), excipients (glycerol, anhydrous sodium phosphate, metacresol, phenol, protamine sulfate, sodium hydroxide, zinc oxide, hydrochloric acid, water for injection- up to 1 ml |
Hypoglycemic agent, intermediate-acting insulin. |
| Wozulim-R |
human insulin (recombinant) – 100 IU (3.5 mg); Glycerol – 16.32 mg, metacresol – 2.50 mg, sodium hydroxide – 0.40 mg, sodium citrate dihydrate – 0.19 mg, zinc oxide – 0.031 mg, citric acid monohydrate – 0.0021 mg, hydrochloric acid – 0.001 ml, water for injection – up to 1 ml. |
Hypoglycemic agent – short-acting insulin |
| Wozulim-30/70 |
human insulin (genetically engineered) – 100 IU (4.0 mg); protamine sulfate – 0.28 mg, zinc oxide – 0.032 mg, metacresol – 1.60 mg, phenol – 0.65 mg, glycerol – 16.32 mg, sodium hydroxide – 0.40 mg, disubstituted anhydrous sodium phosphate – 2, 08 mg, hydrochloric acid – 0.00072 ml, water for injection – up to 1 ml. |
A hypoglycemic agent is a combination of short-acting and intermediate-acting insulins. |
| Spasgel |
ketoprofen – 2.5 g. carbomer 940 (carbopol 980), methyl parahydroxybenzoate, trometamol, lavender oil, polyester PE 240, ethanol (ethyl alcohol) 95%, purified water. |
Non-steroidal anti-inflammatory drugs for topical use. |
| Glaritus |
“Active substance: Insulin glargine** (Manufacturer Specification) 100 IU** (equivalent to 3.6378 mg) Excipients: Glycerol (85%) 20.00 mg Metacresol 2,70 mg Zinc Chloride [equivalent to 30 mcg of zinc] 0,0625 mg Sodium hydroxide 1M q.s. to adjust pH to 4.0 Hydrochloric acid 1M q.s. to adjust pH to 4.0 Water for injection up to 1.0 mL |
The drug GLARITUS belongs to the pharmacotherapeutic group: agents for the treatment of diabetes mellitus; insulins and their analogues; long-acting insulins and their analogues for injection. |
